60-64岁男性心血管筛查结局:DANCAVAS II试验
DANCAVAS II是一项基于人群的平行随机对照试验,将丹麦60-64岁男性按1:4随机分为邀请筛查组(5,946人,其中3,720人实际接受筛查)和对照组(25,322人)。筛查涵盖冠状动脉钙化评分、动脉瘤、心房颤动、外周动脉疾病、高血压、糖尿病和高胆固醇血症,干预包括他汀、阿司匹林和监测。
核心结论
- 邀请60-64岁男性参加基于CT的综合亚临床心血管疾病筛查未降低7年死亡风险,但增加了严重出血。
- 因试验按10年事件设计把握度,需进一步随访。
研究设计与样本
- 基于人群的平行随机对照试验,丹麦60-64岁男性按1:4随机分为邀请筛查组(5,946人)和对照组(25,322人),共31,268人。
- 分配基于计算机生成的随机数并按市镇分层,仅对照组设盲。
- 筛查包括冠状动脉钙化评分、动脉瘤、心房颤动、外周动脉疾病、高血压、糖尿病和高胆固醇血症;干预包括他汀、阿司匹林和监测。
临床怎么用
- 对60-64岁男性,不应仅凭综合CT筛查以降低死亡为目的常规邀请。
- 筛查后干预(含他汀、阿司匹林)需权衡严重出血风险,尤其胃肠道出血。
局限性
- 仅对照组设盲,邀请组和治疗分配非盲。
- 试验按10年事件设计把握度,7年随访可能不足以检出死亡获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Limited data suggest a benefit of population-based screening for cardiovascular disease (CVD) with respect to mortality. METHODS: A population-based, parallel-randomized controlled trial of Danish men aged 60-64 years randomized 1:4 to invitation to screening for subclinical CVD or no invitation (control group) were performed. Allocation was based on computer-generated random numbers and stratified on municipality. Only the control group was blinded. The screening included coronary artery calcification score, aneurysms, atrial fibrillation, peripheral arterial disease, hypertension, diabetes mellitus and hypercholesterolemia. Intervention included statin, aspirin and surveillance. The primary outcome was all-cause mortality. RESULTS: 31,268 participants were randomized; 25,322 men in the control arm and 5,946 in the invited arm, of whom 3,720 attended and were screened (62·6%). In intention-to-treat analyses, after a median follow-up of 7·0 years, 555 (9.3%) men in the intervention group and 2,509 (9·9%) men in the control group had died; hazard ratio (HR) = 0.94 (95% CI: 0·86;1·03), p=0·169.Major adverse cardiovascular events (MACE) were registered in 606 (10·2%) versus 2,682 (10·6%) (HR=0·96 [95% CI 0·88;1.04]; p=0·319).Severe bleedings were significantly more common in the invited-to-screening group (6·0% versus 5·1%; HR=1·18 [95% CI 1·05;1·32]; p=0·007). This included intracranial (HR=1·23 (95% CI 0·96;1·58); p=0·097) and gastrointestinal bleedings (HR=1·18; (95% CI 1·03;1·34) p=0·014), respectively. CONCLUSIONS: Invitation to a comprehensive CT-based screening for subclinical CVD did not decrease death over 7 years among men aged 60-64 years but did increase severe bleeding. Because the trial was powered for events over 10 years, further follow-up is needed. Clinicaltrials.gov number: NCT03946410.
引用
- Lindholt JS, Mejldal A, Rasmussen LM, et al. Outcomes of cardiovascular screening in men aged 60-64 years: the DANCAVAS II trial. Eur Heart J. 2025. PMID: 40884758. doi:10.1093/eurheartj/ehaf704
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。